BIALOOM LTD

Their core work

BIALOOM LTD is a Cyprus-based technology SME working at the intersection of nanophotonics and sensing applications. Their core activity is developing miniaturized, chip-integrated optical sensor systems using plasmo-photonic principles — combining plasmonics and photonics to detect biological and chemical signals at very small scales. They have demonstrated interest in two concrete application domains: rapid medical diagnostics (sepsis detection at point of care) and food quality monitoring (fruits and vegetables value chain analysis). As a small company, they function as a specialist technology contributor, bringing plasmo-photonic integration expertise into research consortia while pursuing their own commercial sensor concepts via EU SME instruments.

What they specialise in

How they've shifted over time

BIALOOM's H2020 history opens with a focused medical device concept — the SepsiCare SME Phase 1 feasibility study in 2020 explored a rapid sepsis sensor chip, but left no technical keywords, typical of early-stage commercial scoping work. Their subsequent involvement in GRACED (2021–2024) reveals the underlying technology platform: plasmo-photonics, interferometers, quantum dots, and on-chip light sources, now applied across both health and food sectors. The shift from a single-disease medical application to a broad-spectrum plasmo-photonic sensing platform suggests BIALOOM is moving from problem-specific prototyping toward a reusable sensor architecture with multiple market entry points.

BIALOOM is evolving toward a platform technology play — building a generic plasmo-photonic sensor base that can address both clinical diagnostics and food quality markets, which positions them as a potential OEM component or IP licensor rather than a single-product company.

How they like to work

BIALOOM has coordinated once (the SME-1 Phase 1, which is effectively a solo feasibility grant) and joined one substantial research consortium as a participant. Their 17 unique partners across 8 countries from just 2 projects indicates that the GRACED consortium is sizeable and internationally distributed, meaning BIALOOM operates comfortably within large multi-partner research projects. As a small specialist company, they are best understood as a focused technology contributor rather than a project manager — they bring specific photonic device expertise and benefit from the broader scientific infrastructure of larger consortia.

BIALOOM has built connections with 17 distinct consortium partners across 8 countries through just 2 projects, suggesting their GRACED participation placed them in a well-networked European photonics research consortium. No repeated partner patterns are visible given the small project count, so geographic loyalty cannot yet be assessed.

What sets them apart

BIALOOM occupies a rare niche as a Cypriot SME with genuine deep-tech photonics credentials — most Cyprus-based private companies in H2020 appear in business or services roles, while BIALOOM is contributing to cutting-edge plasmo-photonic sensor research. Their dual-domain focus on medical diagnostics and food quality gives them a cross-sector bridge that is genuinely uncommon: few photonics SMEs can credibly address both clinical point-of-care and agri-food analytical markets. For consortium builders in health-tech or food-tech seeking a specialist photonics integrator from Southern Europe, BIALOOM offers both the technical profile and SME flexibility that large research institutes cannot match.

Highlights from their portfolio

• GRACED
  The flagship project by funding and scope — EUR 390,938 as a participant in a multi-country RIA consortium developing plasmo-photonic multiplexing sensor platforms with applications spanning both healthcare biosensing and food quality monitoring.
• SepsiCare
  Notable as BIALOOM's only coordinator role and their earliest public proof-of-concept: a commercial feasibility study for a multi-sensor sepsis diagnostic chip, showing the medical device ambition behind their photonic sensor work.